Completed
Phase 3
Age: 18Years - 100Years
All Genders
ID00000560
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2016-04-14
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.
CONDITIONS
Official Title
Beta-Blocker Evaluation in Survival Trial (BEST)
Who Can Participate
Age: 18Years - 100Years
All Genders
Eligibility Criteria
You may qualify if you...
Men and women, ages 18 and over. Patients had compensated congestive heart failure due to idiopathic dilated cardiomyopathy or coronary disease with ejection fraction less than or equal to 0.35, were in the New York Heart Association functional class III or IV, and were taking an angiotensin-converting enzyme inhibitor, digitalis, and if needed, a diuretic. Patients with a specific indication for, or contraindication to, beta-blockade were excluded.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.
Beta-Blocker Evaluation of Survival Trial Investigators, Eric J Eichhorn, Michael J Domanski...
https://pubmed.ncbi.nlm.nih.gov/11386264Comparison of the beta blocker bucindolol in younger versus older patients with heart failure.
Juan M Aranda, Heidi J Krause-Steinrauf, Barry H Greenberg...
https://pubmed.ncbi.nlm.nih.gov/12031741Failure of benefit and early hazard of bucindolol for Class IV heart failure.
Jeffrey L Anderson, Heidi Krause-Steinrauf, Steven Goldman...
https://pubmed.ncbi.nlm.nih.gov/13680547The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.
Michael Domanski, Heidi Krause-Steinrauf, Prakash Deedwania...
https://pubmed.ncbi.nlm.nih.gov/12957443Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST).
Eric J Eichhorn, Paul A Grayburn, Susan A Mayer...
https://pubmed.ncbi.nlm.nih.gov/14597587Gender differences in advanced heart failure: insights from the BEST study.
Jalal K Ghali, Heidi J Krause-Steinrauf, Kirkwood F Adams...
https://pubmed.ncbi.nlm.nih.gov/14680739Hormone replacement therapy is associated with improved survival in women with advanced heart failure.
JoAnn Lindenfeld, Jalal K Ghali, Heidi J Krause-Steinrauf...
https://pubmed.ncbi.nlm.nih.gov/14522488Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
M R Bristow, H Krause-Steinrauf, R Nuzzo...
https://pubmed.ncbi.nlm.nih.gov/15337700Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy.
Christopher M O'Connor, Steven Gottlieb, Jamieson M Bourque...
https://pubmed.ncbi.nlm.nih.gov/15721091